Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: A report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial

Japanese Journal of Clinical Oncology

Volumn 39, Issue 11, 2009, Pages 713-719

  Koizumi, Wasaburo ^a   Akiya, Toshikazu ^b   Sato, Atsushi ^c   Yamaguchi, Kensei ^d   Sakuyama, Toshikazu ^e   Nakayama, Norisuke ^f   Tanabe, Satoshi ^a   Higuchi, Katsuhiko ^a   Sasaki, Tohru ^a   Sekikawa, Takashi ^c  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b GUNMA PREFECTURAL CANCER CENTER   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAITAMA CANCER CENTER   (Japan)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

Author keywords

Advanced gastric cancer; Biweekly paclitaxel; Second line chemotherapy

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CAPECITABINE; CISPLATIN; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; UFT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER TOXICITY; MALE; MOTOR NEUROPATHY; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; RECURRENT CANCER; SENSORY NEUROPATHY; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA;

AGED; ANOREXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRIMIDINES; STOMACH NEOPLASMS; TOKYO; TREATMENT OUTCOME;

EID: 70449344262     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp099     Document Type: Article

References (26)

1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
2. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 2000;58:191-7.
3. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
4. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Nagashima F, et al. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003;89:2207-12.
5. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Proc Am Soc Clin Oncol 2007;25:LBA4513.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008;9:215-21.
7. Futatsuki K, Wakui A, Nakao I, Sakata Y, Kambe M, Shimada Y, et al. Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8.
8. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998;21:416-9.
9. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.
10. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-5.
11. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 1998;25:1915-24.
12. Mai M, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (group B). Gan To Kagaku Ryoho 1999;26:487-96.
13. Noda K, Ikeda M, Kudo R, Nishiya I, Yajima A, Tanaka K, et al. Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion. BMS-181339 Ovarian Cancer Study Group. Gan To Kagaku Ryoho 1996;23:317-25.
14. Yoneda S, Nishiwaki Y, Niitani H, Kurita Y, Ariyoshi Y, Ikegami H, et al. Early phase II study of BMS-181339 (paclitaxel) in patients with non-small cell lung cancer. BMS-181339 Non-Small Cell Lung Cancer Study Group. Gan To Kagaku Ryoho 1996;23:695-701.
15. Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, et al. Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. West Japan Lung Cancer Group. Oncology 1997;54:298-303.
16. Ito Y, Horikoshi N, Watanabe T, Sasaki Y, Tominaga T, Okawa T, et al. Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan. BMS-181339 Breast Cancer Study Group. Invest New Drugs 1998;16:183-90.
17. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. A randomized multicenter study of single agent paclitaxel (TAXOL) given weekly versus every three weeks to patients (pts) with ovarian cancer (OC) previously treated with platinum therapy. Proc Am Soc Clin Oncol 1999;18:368a.
18. Emi Y, Yamamoto M, Takahashi I, Orita H, Kakeji Y, Kohnoe S, et al. Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today 2008;38:1013-20.
19. Arai T, Hamaguchi T, Shirao K, Shimada Y, Yamada Y, Muro K, et al. Weekly paclitaxel (PTX) in patients with heavily treated advanced gastric cancer (AGC). Jpn J Cancer Clin 2003;49:621-5.
20. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res 2007;27:2667-71.
21. Gelmon KA, Tolcher A, O'Reilly S, Campbell C, Bryce C, Shenkier T, et al. A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer. Ann Oncol 1998;9:1247-9.
22. Koizumi W, Tanabe S, Higuchi K, Sasaki T, Nakayama S, Nakatani K, et al. Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer. Anticancer Res 2006;26:3797-802.
23. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
24. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: Final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-9.
25. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-71.
26. Isonishi S, Yasuda M, Takahashi F, Katsumata N, Kimura E, Aoki D, et al. Randomized phase III trial of conventional paclitaxel and carboplatin (c-TC) versus dose dense weekly paclitaxel and carboplatin (dd-TC) in women with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Japanese Gynecologic Oncology. Proc Am Soc Clin Oncol 2008;abstract 5506.